INDIANAPOLIS— Eli Lilly is accelerating its push toward preventive medicine by expanding investments in obesity, cardiovascular disease, Alzheimer's disease and other conditions, underscoring a broader shift among large pharmaceutical companies toward preventing illness before it progresses rather than treating advanced disease.
The U.S. drugmaker has used strong revenue growth from its diabetes and obesity medicines to fund acquisitions, manufacturing expansion and research across a wider pipeline of preventive and early-intervention therapies. In April, Lilly raised its full-year financial guidance after reporting a 56% increase in first-quarter revenue, citing demand for products including Mounjaro and the U.S. launch of oral obesity medicine Foundayo (orforglipron).
Chief Executive David Ricks has said the company is investing heavily in medicines designed to address chronic diseases earlier in their progression while expanding production capacity to meet expected long-term demand. Lilly has also increased spending on artificial intelligence, genetic medicine and biotechnology partnerships intended to accelerate drug discovery.
The company's strategy extends beyond obesity. Earlier this month, Lilly announced it would present new Alzheimer's disease research, including studies evaluating blood-based diagnostic tests and additional data on its amyloid-targeting therapy at the Alzheimer's Association International Conference, reflecting continued investment in earlier diagnosis and treatment.
Lilly has also continued expanding through acquisitions. This week, it agreed to acquire AtaiBeckley in a deal worth up to $3.8 billion, adding a late-stage psychedelic therapy for treatment-resistant depression to its pipeline as it broadens its portfolio beyond metabolic diseases.
Industry analysts say major drugmakers are increasingly focusing on preventive care, supported by advances in genetics, artificial intelligence and earlier disease detection. The approach is intended to reduce the long-term burden of chronic illnesses while creating opportunities for medicines that can be used before irreversible damage occurs.
Competition remains intense, particularly in the obesity market where Lilly and Denmark's Novo Nordisk are investing billions in new medicines, manufacturing capacity and expanded patient access. Analysts expect both companies to continue competing across injectable and oral therapies as demand for metabolic disease treatments grows.
Lilly has said it will continue investing in research, manufacturing and business development as it seeks to broaden its portfolio of medicines aimed at preventing or slowing the progression of chronic diseases, with additional clinical trial results and regulatory milestones expected later this year.
